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SCOPE
This clinical practice guideline has been developed to provide
recommendations for the treatment of patients already
diagnosed with glomerulonephritis (GN). The emphasis is
on the more common forms of immune-mediated glomer-
ular disease in both children and adults. The scope includes
histologic variants of GN restricted to the kidney, as well as
the most common ones associated with systemic immune-
mediated disease. This guideline does not cover diagnosis or
prevention of GN.
The guideline addresses the following forms of GN:
K Steroid-sensitive nephrotic syndrome (SSNS) and steroid-
resistant nephrotic syndrome (SRNS) in children;
K Minimal-change disease (MCD) and idiopathic focal
segmental glomerulosclerosis (FSGS) in children and
adults;
K Idiopathic membranous nephropathy (IMN);
K Idiopathic membranoproliferative GN;
K GN associated with infections;
K Immunoglobulin A (IgA) nephropathy and Henoch-
Scho¨nlein purpura (HSP) nephritis;
K Lupus nephritis (LN);
K Renal vasculitis;
K Antiglomerular basement membrane (anti-GBM) GN.
METHODOLOGY
The Work Group members defined the overall topics and goals
for the guideline. Then, in collaboration with the evidence
review team (ERT), the Work Group further developed and
refined each systematic review topic, specified screening
criteria, literature search strategies, and data extraction forms.
The ERT performed literature searches, organized the
abstracts and article screening, coordinated the methodologi-
cal and analytic processes of the report, defined and
standardized the methodology relating to these searches and
data extraction, and produced summaries of the evidence.
Using the Grading of Recommendations Assessment, Develop-
ment and Evaluation (GRADE) approach, they created
preliminary evidence profiles (described in the Methods for
guideline development) that were subsequently reviewed and
completed by the Work Group members. The ERT searches
were updated to January 2011 and supplemented with
additional studies known to the Work Group members through
November 2011. Through an iterative process that involved all
Work Group members, the chairs of the Work Group, and the
ERT, the individual chapters were refined, reviewed, and
finalized. All the details in the multiple steps involved in the
assessment of grade and strength of the evidence are detailed
fully in the section, Methods for guideline development. The
Work Group made two levels of recommendations (1 or 2)
based on the strength of the evidence supporting the
recommendation, the net medical benefit, values and prefer-
ences, and costs. Recommendations were also graded based on
the overall quality of the evidence (A to D). Recommendations
that provided general guidance about routine medical care (and
related issues) were not graded.
The recommendations made in this guideline are directed
by the available evidence to support the specific treatment
options listed. When the published evidence is very weak
or nonexistent no recommendations are made, although the
reasons for such omissions are explained in the rationale in
each chapter. There are, therefore, a number of circumstances
in this guideline where treatments in wide use in current
clinical practice are given only level 2 recommendations
(i.e., suggested) or not included for lack of evidence.
The starting point for this guideline is that a morpho-
logical characterization of the glomerular lesion has been
established by kidney biopsy or, in the case of some children
with nephrotic syndrome, by characteristic clinical features.
An important corollary is that the guideline does not provide
recommendations on how to evaluate patients presenting
with suspected glomerular disease nor when or in whom to
perform a diagnostic kidney biopsy. We recognize these are
relevant management issues in these patients but have chosen
to begin the guideline at the point of an established diagnosis
based on an adequate biopsy reviewed by a knowledgeable
nephropathologist. This has dictated the starting point of our
evidence-based systematic reviews and subsequent recom-
mendations.
INTENDED USERS
This guideline was written primarily for nephrologists,
although it should also be useful for other physicians, nurses,
pharmacists, and health-care professionals who care for
patients with GN. It was not developed for health-care
administrators or regulators per se, and no attempts were
made to develop clinical performance measures. This guide-
line was also not written directly for patients or caregivers,
though appropriately drafted explanations of guideline
recommendations could potentially provide useful informa-
tion for these groups.
DISCLAIMER
While every effort is made by the publishers, editorial board,
and ISN to see that no inaccurate or misleading data, opinion
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or statement appears in this Journal, they wish to make it
clear that the data and opinions appearing in the articles and
advertisements herein are the responsibility of the contri-
butor, copyright holder, or advertiser concerned. Accord-
ingly, the publishers and the ISN, the editorial board and
their respective employers, office and agents accept no
liability whatsoever for the consequences of any such
inaccurate or misleading data, opinion or statement. While
every effort is made to ensure that drug doses and other
quantities are presented accurately, readers are advised that
new methods and techniques involving drug usage, and
described within this Journal, should only be followed in
conjunction with the drug manufacturer0s own published
literature.
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